

**** Materials for this course will be release on 10/21/2020 ****

Pediatric Pharmacy Specialty Recertification Literature Study: Module 2A-B (Cert # L209213)

Teaser: The Literature Study Module provides immediate access to peer-selected, contemporary articles that are relevant to specialty practice. After learners review the content, they must successfully complete an online assessment to earn recertification credit.

Tag: Certifications; Pediatrics



ACPE Numbers: Various – see listing below

Pre-Sale Date: 09/23/2020

Content Release Date: 10/21/2020

Expiration Dates: 04/20/2021

Activity Type: Application-based

CE Credits: 10 hours

Activity Fee: \$55 (ASHP member); \$110 (non-member)

Accreditation for Pharmacists



The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Target Audience

These Literature Studies are designed to help board-certified pharmacists who are seeking recertification credit hours to maintain their Board of Pharmacy Specialties (BPS).

Activity Overview

The Literature Study Module is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by the Board of Pharmacy Specialties (BPS). This module consists of 2 online home study activities (see table below). Each activity is designed to assess the learners' ability to analyze and apply peer-selected contemporary articles to practice and includes a short video for enhanced learning and understanding.

Module 2A—Critical Care/General Pediatrics: This module focuses on newly-released pediatric guidelines for severe traumatic brain injury, treatment of convulsive status epilepticus in children, and monoclonal antibody treatment of RSV in young infants.

Module 2B—General Pediatrics: This module focuses on newly-released pediatric migraine prevention and treatment guidelines.

Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this Literature Study, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.

These activities are part of the ASHP professional development program for BCPPS recertification approved by the BPS.

**** Materials for this course will be release on 10/21/2020 ****

Recertification Credit*

Board certified pharmacists are eligible to receive up to 10 hours of recertification credit for completing this module. To earn recertification credit, learners must review the activity content and successfully complete the online assessments by the deadline. Only completed assessments will be eligible for credit; no partial or incomplete assessments will be processed. You are allowed only one attempt to successfully complete this assessment.

Learning Activity	ACPE Number	Credit Hours	*Assessment Pass Point
Pediatric Pharmacy Literature Study Module 2A: Critical Care/General Pediatrics	0204-0000-20-966-H01-P	5	80%
Pediatric Pharmacy Literature Study Module 2B: General Pediatrics	0204-0000-20-967-H01-P	5	80%

Articles and Learning Objectives

Module 2A: Critical Care/General Pediatrics

ACPE#: 0204-0000-20-966-H01-P

This module focuses on newly-released pediatric guidelines for severe traumatic brain injury, treatment of convulsive status epilepticus in children, and monoclonal antibody treatment of RSV in young infants.

Kochanek PM, et al. Guidelines for the Management of Pediatric Severe Traumatic Brain Injury, Third Edition: Update of the Brain Trauma Foundation Guidelines, Executive Summary. *Pediatr Crit Care Med*. 2019 Mar; 20(3):280-289.

Learning Objectives:

- Describe the third edition of the Brain Trauma Foundation guidelines for the management of pediatric severe traumatic brain injury (TBI) and the algorithm with first and second tier therapies for managing pediatric severe TBI.
- Develop recommendations for the management of pediatric patients with severe traumatic brain injury.

Kochanek PM, et al. Management of Pediatric Severe Traumatic Brain Injury: 2019 Consensus and Guidelines-Based Algorithm for First and Second Tier Therapies. *Pediatr Crit Care Med*. 2019 Mar; 20(3):269-279.

Learning Objectives:

- Describe the third edition of the Brain Trauma Foundation guidelines for the management of pediatric severe traumatic brain injury (TBI) and the algorithm with first and second tier therapies for managing pediatric severe TBI.
- Develop recommendations for the management of pediatric patients with severe traumatic brain injury.

Dalziel SR, Borland ML, Furyk J, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. *Lancet*. 2019 May 25; 393(10186):2135-2145. doi: 10.1016/S0140-6736(19)30722-6. Epub 2019 Apr 17.

<https://www.ncbi.nlm.nih.gov/pubmed/31005386>.

Learning Objectives:

- Explain the rationale, methodology, findings, limitations, and implications of the Convulsive Status Epilepticus Paediatric Trial (ConSEPT) comparing phenytoin with levetiracetam as second-line therapy after failure of benzodiazepine treatment.
 - Develop recommendations for the treatment of convulsive status epilepticus in pediatric patients.
-

**** Materials for this course will be release on 10/21/2020 ****

Alansari K, et al. Monoclonal antibody treatment of RSV bronchiolitis in young infants: A randomized trial. *Pediatrics*. 2019 Mar; 143 (3): Epub 2019 Feb 13.

Learning Objectives:

- Explain the rationale, methodology, findings, limitations, and implications of the study of palivizumab for treatment of respiratory syncytial virus (RSV) bronchiolitis in young infants
- Develop recommendations for the treatment of respiratory syncytial virus (RSV) bronchiolitis in young infants

Module 2B: General Pediatrics

ACPE#: 0204-0000-20-967-H01-P

This module focuses on newly-released pediatric migraine prevention and treatment guidelines.

Oskoui M, Pringsheim T, Billingham L, et al. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology*. 2019 Sep 10; 93(11):500-509.

Learning Objectives:

- Describe the American Academy of Neurology and American Headache Society practice guideline update summary on pharmacologic treatment for pediatric migraine prevention.
- Develop recommendations for pharmacologic prevention of migraine in pediatric patients.

Oskoui M, Pringsheim T, Holler-Managan Y, et al. Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. *Headache*. 2019 Sep; 59(8):1158-1173.

Learning Objectives:

- Describe the American Academy of Neurology and American Headache Society practice guideline update summary on acute treatment of migraine in children and adolescents.
- Develop recommendations for the acute treatment of migraine in children and adolescents.

Faculty

Lea Eiland, Pharm.D., BCPS, BCPPS, FASHP, FPPAG
Clinical Professor and Associate Department Head
Auburn University Harrison School of Pharmacy
Auburn, Alabama

Valerie Nolt, Pharm.D., BCPPS
Clinical Pharmacist Specialist
Rockford, Michigan

Stephanie Weightman, Pharm.D., R.Ph., BCPPS, BCPS
Clinical Pharmacist - Emergency Department
Children's Medical Center Dallas
Dallas, Texas

**** Materials for this course will be release on 10/21/2020 ****

Content Matter Experts

Peter Johnson, Pharm.D., BCPPS, BCPS, FCCM, FPPAG
President's Associate Presidential Professor
Director, PGY2 Pediatric Pharmacy Residency
Director, Clinical and Translational Science Fellowship in Pediatric Pharmacotherapy
Director, Pediatric Pharmacotherapy Degree Option
The University of Oklahoma College of Pharmacy
Clinical Pharmacy Specialist—Pediatric Critical Care
The Children's Hospital at OU Medical Center

Jamie Miller, Pharm.D., BCPPS, BCPS, FPPAG
Associate Professor
University of Oklahoma College of Pharmacy
Oklahoma City, Oklahoma

Jennifer Thackray, Pharm.D., BCPPS, BCPS
Pediatric Oncology Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, New York

Reviewers

Michelle C. Abalos, Pharm.D.
Susan R. Dombrowski, B.S.Pharm., M.S.
Kristi N. Hofer, Pharm.D.

Field Testers

Soliman Aly, MSc. Clinical Pharmacy
Meghan Baldo, Pharm.D., BCPPS
Danielle Ball, Pharm.D., BCPPS
Monica Bogenschuz, Pharm.D., BCPS, BCPPS
Allison Chung, Pharm.D., BCPS
Melissa Cook, Pharm.D., BCPPS
Tasnim Dawoud, Pharm.D., MSc., BCPPS
Heather Dedman, BSP, BCPPS
Debra Determan, Pharm.D., BCPPS
Darrin Dillingham, Pharm.D., BCPPS
Jessica Frye, Pharm.D., BCPPS
Sandra Garner, Pharm.D., BCPS, BCPPS, FCCP
Karen Gradischer, Pharm D., BCPPS
Sarah Hale, Pharm.D., BCPPS
Aaron Harthan, Pharm.D., BCPPS
Alyssa Hobby, Pharm.D., BCPPS
Rita Jew, Pharm.D., M.B.A., BCPPS, FASHP
Jenna Kaplan, Pharm.D., BCPPS
Katelin Kimler, Pharm.D., BCPPS
Karen Kovey, Pharm.D., BCPS, BCPPS
Ekaterina Kurdyukova, Pharm.D., BCPPS
Emily Kurzen, Pharm.D., BCPPS
Biljana Lanier, B.S.Pharm., BCPPS

**** Materials for this course will be release on 10/21/2020 ****

Man Soi Lo, BCCCP
Thao Ngo, B.Pharm, M.Sc., BCPPS
Hong Nguyen, Pharm.D., BCPPS
Sarah Parsons, Pharm.D., BCPPS
Amanda Penland, Pharm.D.; BCPPS
Michael Raschka, Pharm.D., BCPPS
Joan Stumpe, Pharm.D.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support and the Accreditation Council for Pharmacy Education's Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual's participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

If no one in the session has anything to disclose:

All other planners, presenters, reviewers, ASHP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Methods and CE Requirements

Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:

- Complete the attestation statement
- Review all content
- Complete and pass the assessments
- Complete the evaluations

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the [minimum technical and system requirements](#) for learning activities.

Development

These activities were developed by ASHP.